Search results for " acetylcholine"

showing 10 items of 239 documents

Association of a variant in the muscarinic acetylcholine receptor 2 gene (CHRM2 ) with nicotine addiction

2009

Genetic factors contribute to the overall risk of developing nicotine addiction, which is the major cause of preventable deaths in western countries. However, knowledge regarding specific polymorphisms influencing smoking phenotypes remains scarce. In the present study we provide evidence that a common single nucleotide polymorphism (SNP) in the 5′ untranslated region of CHRM2, the gene coding for the muscarinic acetylcholine receptor 2 is associated with nicotine addiction. CHRM2 was defined as a candidate gene for nicotine addiction based on previous evidence that linked variations in CHRM2 to alcohol and drug dependence. A total of more than 5,500 subjects representative of the German po…

AdultMaleNicotineCandidate geneAdolescentmedia_common.quotation_subjectSingle-nucleotide polymorphismBiologyBioinformaticsNicotineCellular and Molecular NeuroscienceMuscarinic acetylcholine receptormedicineHumansSNPGenetic Predisposition to DiseaseAlleleAllelesGenetics (clinical)Agedmedia_commonAged 80 and overGeneticsReceptor Muscarinic M2AddictionSmokingGenetic VariationTobacco Use DisorderOdds ratioMiddle AgedPsychiatry and Mental healthFemalemedicine.drugAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics
researchProduct

Blockade of nicotinic and muscarinic receptors facilitates spontaneous migration of human peripheral granulocytes: failure in cystic fibrosis.

2012

Circulating leucocytes express muscarinic (m) and nicotinic (n) receptors and synthesize acetylcholine (ACh) regulating various cell functions. Leucocytes from patients with cystic fibrosis contain less ACh; therefore it was tested whether the regulation of cellular functions like migration differed from healthy volunteers.Peripheral blood (10-20 ml) was used, leucocytes were isolated by Ficoll® gradient and the commercial MIGRATEST® combined with flow cytometric analysis was applied (pore size 3 μm).In the absence of test substances 4900±1800 (n=10) leucocytes migrated within a time period of 2 h. In the presence of tubocurarine (TC, 30 μM) the cell number increased to 7500±2700 [n=10] cor…

AdultMalemedicine.medical_specialtyAdolescentCystic FibrosisBiologyReceptors NicotinicGeneral Biochemistry Genetics and Molecular BiologyCholinergic AntagonistsYoung AdultCell Migration Assays LeukocyteCell MovementInternal medicineMuscarinic acetylcholine receptormedicineMuscarinic acetylcholine receptor M4HumansGeneral Pharmacology Toxicology and PharmaceuticsReceptorChildMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2General MedicineReceptors MuscarinicNicotinic agonistEndocrinologyCholinergicFemaleAcetylcholinemedicine.drugGranulocytesLife sciences
researchProduct

Increased sensitivity of the neuronal nicotinic receptor alpha-2 subunit causes familial epilepsy with nocturnal wandering and ictal fear

2006

Sleep has traditionally been recognized as a precipitating factor for some forms of epilepsy, although differential diagnosis between some seizure types and parasomnias may be difficult. Autosomal dominant frontal lobe epilepsy is characterized by nocturnal seizures with hyperkinetic automatisms and poorly organized stereotyped movements and has been associated with mutations of the α4 and β2 subunits of the neuronal nicotinic acetylcholine receptor. We performed a clinical and molecular genetic study of a large pedigree segregating sleep-related epilepsy in which seizures are associated with fear sensation, tongue movements, and nocturnal wandering, closely resembling nightmares and sleep …

AdultMalemedicine.medical_specialtyAdolescentSomnambulismMolecular Sequence DataMutation MissenseAutosomal dominant nocturnal frontal lobe epilepsyReceptors NicotinicBiologymedicine.disease_causeLigandsNicotinicArticleEpilepsyBIO/09 - FISIOLOGIAInternal medicineAcetylcholine; Adolescent; Adult; Aged; Aged 80 and over; Amino Acid Sequence; Epilepsy; Female; Humans; Ligands; Male; Molecular Sequence Data; Mutation Missense; Neurons; Pedigree; Receptors Nicotinic; Somnambulism; FearReceptorsmedicine80 and overGeneticsHumansIctalGenetics(clinical)Amino Acid SequenceGenetics (clinical)Acetylcholine receptorAgedAged 80 and overNeuronsMutationEpilepsySeizure typesFearmedicine.diseaseAcetylcholinePedigreeNicotinic acetylcholine receptorNicotinic agonistEndocrinologyMutationnAChR patch-clamp ADNFLE sleep-related epilepsy M1 TM1 ACh nicotineSettore MED/26 - NeurologiaFemaleMissense
researchProduct

Smoking cessation and variations in nicotinic acetylcholine receptor subunits alpha-5, alpha-3, and beta-4 genes.

2009

Background Evidence has recently accumulated that single nucleotide polymorphisms in the genetic region encoding the nicotinic acetylcholine receptor subunits α-5, α-3, and β-4 are associated with smoking and nicotine dependence. We aimed to determine whether these genetic variations are also predictive of smoking cessation. Methods Lifetime history of smoking was assessed by questionnaire at enrolment into a large epidemiological study of the German elderly population (ESTHER study). Cox proportional hazards modeling was applied in a retrospective cohort approach to determine the associations of individual polymorphisms and haplotypes with smoking cessation probability in 1446 subjects who…

AdultMalemedicine.medical_treatmentPopulationPhysiologySingle-nucleotide polymorphismNerve Tissue ProteinsReceptors NicotinicPolymorphism Single NucleotideGenetic determinismCohort StudiesmedicineHumanseducationBiological PsychiatryAgedGeneticseducation.field_of_studybusiness.industryProportional hazards modelHaplotypeMiddle AgedNicotinic acetylcholine receptorGenetic epidemiologyHaplotypesSmoking cessationFemaleSmoking CessationbusinessBiological psychiatry
researchProduct

Cellular Distribution and Expression of Cortical Acetylcholine Receptors in Aging and Alzheimer's Disease

1991

Ligand binding studies show marked reductions of nicotinic, but not of muscarinic binding sites in Alzheimer's disease. Using monoclonal antibodies we studied immunohistochemically the expression of the respective receptor proteins in the frontal cortex of middle-aged (55 +/- 5 yr) controls, age-matched controls (73 +/- 6 yr), and patients with Alzheimer's disease (74 +/- 5 yr). Density of nicotinic cholinoceptive neurons was 8000/mm3 for middle-aged controls and 4000/mm3 for age-matched controls, but only 900/mm3 in Alzheimer's brains (p less than 0.0001). Densities of muscarinic cholinoceptive and of Nissl-stained neurons were not significantly different between the groups, pointing to a …

Agingmedicine.medical_specialtyCORTEXGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of ScienceAlzheimer DiseaseInternal medicineMuscarinic acetylcholine receptormedicineHumansReceptors CholinergicBinding siteReceptorNEURONSAcetylcholine receptorCerebral CortexChemistryGeneral Neurosciencemedicine.diseaseCHOLINOCEPTORSCortex (botany)medicine.anatomical_structureEndocrinologyNicotinic agonistCerebral cortexAlzheimer's disease
researchProduct

Behavioral effects of different enriched environments in mice treated with the cholinergic agonist PNU-282987.

2013

Abstract Environmental enrichment is an experimental model in which rodents are housed in complex environments that favor lower levels of anxiety-like behavior. PNU-282987 (PNU) is a α7 nicotinic acetylcholine receptor agonist with beneficial effects on learning though its effects on anxiety are unclear. Our main aim was to carry out a study of its effects in NMRI ( n  = 96) mice reared in different environments: environmental enrichment (EE), Marlau™ cages (MC) and standard environment (SE). After a 4-month period, mice received acute treatment of PNU (2.5, 5 and 10 mg/kg) and were evaluated in the elevated plus-maze (EPM) and hole-board (HB). In the EPM, both EE and MC reared mice showed …

AgonistMalemedicine.medical_specialtyElevated plus mazealpha7 Nicotinic Acetylcholine Receptormedicine.drug_classAnxietyEnvironmentMotor ActivityDevelopmental psychologyBehavioral NeuroscienceBridged Bicyclo CompoundsMiceα7 nicotinic acetylcholine receptorInternal medicinemedicineAnimalsNicotinic AgonistsBeneficial effectsEnvironmental enrichmentBehavior AnimalExperimental modelGeneral MedicineNicotinic agonistEndocrinologyBenzamidesExploratory BehaviorCholinergicAnimal Science and ZoologyPsychologyInjections IntraperitonealBehavioural processes
researchProduct

Glycopyrronium bromide blocks differentially responses mediated by muscarinic receptor subtypes.

1993

To analyse the potency of glycopyrronium bromide in blocking responses mediated via subtypes of muscarinic receptors in vitro, we tried to determine its equilibrium dissociation constants at prejunctional muscarinic receptors inhibiting the twitch response of rabbit vas deferens (presumed M1 type), at M2 (paced at left atria), M3 (guinea pig ileum) muscarinic receptor subtypes and at the muscarinic receptor of the rabbit iris sphincter (not M1-M4, not m5). Glycopyrronium bromide shifted to the right the curve for inhibition of the twitch response induced by the agonist McN-A-343, and the methacholine-induced curves for inhibition of rat atrial contraction, and for tonic contraction of guine…

AgonistMalemedicine.medical_specialtymedicine.drug_classGuinea PigsIrisMuscarinic AntagonistsIn Vitro TechniquesModels BiologicalVas DeferensInternal medicineMuscarinic acetylcholine receptorMuscarinic acetylcholine receptor M4medicineAnimalsMethacholine CompoundsGlycopyrronium bromidePharmacologyChemistryVas deferens(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium ChlorideMuscarinic acetylcholine receptor M3ParasympatholyticsMuscarinic acetylcholine receptor M2HeartMuscle SmoothGeneral MedicineMuscarinic acetylcholine receptor M1GlycopyrrolateRatsEndocrinologymedicine.anatomical_structureFemaleRabbitsmedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Agonist potency differentiates G protein activation and Ca2+ signalling by the orexin receptor type 1.

2005

The G protein coupling characteristics of a flag epitope-tagged orexin receptor type 1 (OX1R) was investigated in HEK293 cells. Immunoprecipitation of the OX1R and immunoblotting revealed interactions with Gq/G11 proteins as well as with Gs and Gi proteins. Stimulation with orexin-A did not affect the ability of the OX1R to coprecipitate Gq/G11 proteins, but it robustly elevated the intracellular concentration of Ca2+, [Ca2+]i. No changes in cAMP levels could be detected upon receptor stimulation. To get further insight into the functional correlation of G protein activation and Ca2+ signalling, we used baculovirus transduction to express chimeric G proteins, containing the Galphas protein …

AgonistReceptors Neuropeptidemedicine.drug_classG proteinBiologyKidneyBiochemistryCell LineReceptors G-Protein-CoupledGTP-binding protein regulatorsGTP-Binding ProteinsOrexin ReceptorsTransduction GeneticMuscarinic acetylcholine receptormedicineCyclic AMPHumansCalcium SignalingPharmacologyReceptor Muscarinic M3Neurotransmitter AgentsOrexinsDose-Response Relationship DrugNeuropeptidesIntracellular Signaling Peptides and ProteinsMuscarinic acetylcholine receptor M3Fusion proteinOrexin receptorCell biologyBiochemistryCalciumSignal transductionBaculoviridaeSignal TransductionBiochemical pharmacology
researchProduct

Introductory Lecture: Allosteric Modulation of Torpedo Nicotinic Acetylcholine Receptor Ion Channel Activity by Noncompetitive Agonists

1997

AbstractSimilar to other neuroreceptors of the vertebrate central nervous system, the nicotinic acetylcholine receptor (nAChR) is subject to modulatory control by allosterically acting ligands. Of particular interest in this regard are allosteric ligands that enhance the sensitivity of the receptor to its natural agonist acetylcholine (ACh), as such ligands could be useful as drugs in diseases associated with impaired nicotinic neurotransmission. Here we discuss the action of a novel class of nAChR ligands which act as allosterically potentiating ligands (APL) on the nicotinic responses induced by ACh and competitive agonists. In addition, APLs also act as noncompetitive agonists of very lo…

Agonistmedicine.drug_classChemistryAllosteric regulationCell BiologyPharmacologyBiochemistryNicotinic acetylcholine receptorNicotinic agonistGanglion type nicotinic receptorMuscarinic acetylcholine receptormedicineAlpha-4 beta-2 nicotinic receptorMolecular BiologyAcetylcholinemedicine.drugJournal of Receptors and Signal Transduction
researchProduct

Acetylcholine and nicotine stimulate the release of granulocyte-macrophage colony stimulating factor from cultured human bronchial epithelial cells.

1998

Primary cultures of human bronchial epithelial cells (HBE-cells) were established to measure granulocyte-macrophage colony stimulating factor (GM-CSF) release. HBE-cells showed a basal GM-CSF release (82+/-20 ng/well/24 h; 30 donors), which was increased by interleukin-1 beta(IL-1beta, 1 ng/ml) by 270%. This effect was blocked by 1 microM dactinomycin or 10 microM cycloheximide, i.e. the stimulatory effect of IL-1beta depended on de-novo synthesis. Histamine (100 microM) and acetylcholine ( 100 nM) stimulated GM-CSF release more than two-fold above the baseline. Nicotine (1 microM) increased GM-CSF release to a similar extent, and this effect was prevented by 30 microM (+)-tubocurarine. The…

Agonistmedicine.medical_specialtyNicotinemedicine.drug_classSubstance PBronchiCycloheximideBiologyNicotinechemistry.chemical_compoundInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineHumansNicotinic AgonistsCells CulturedPharmacologyGranulocyte-Macrophage Colony-Stimulating FactorGeneral MedicineAcetylcholineEndocrinologychemistryHistamineAcetylcholinemedicine.drugHistamineNaunyn-Schmiedeberg's archives of pharmacology
researchProduct